Cargando…

Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors

BACKGROUND: BI 836880 is a humanized bispecific nanobody® that inhibits vascular endothelial growth factor and angiopoietin-2. Here, we report results from two phase I, nonrandomized, dose-escalation studies (NCT02674152 and NCT02689505; funded by Boehringer Ingelheim) evaluating BI 836880 in patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Le Tourneau, C., Becker, H., Claus, R., Elez, E., Ricci, F., Fritsch, R., Silber, Y., Hennequin, A., Tabernero, J., Jayadeva, G., Luedtke, D., He, M., Isambert, N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588896/ https://www.ncbi.nlm.nih.gov/pubmed/36108560 http://dx.doi.org/10.1016/j.esmoop.2022.100576

Ejemplares similares

Comparison of different dosing regimens (once weekly vs. twice weekly, and once weekly vs. once every two weeks) with epoetin delta in patients with chronic kidney disease: a randomized controlled trial
por: Macdougall, Iain C
Publicado: (2007)

Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors
por: Rovithi, Maria, et al.
Publicado: (2019)

Phase I study of gemcitabine using a once every 2 weeks schedule.
por: Vermorken, J. B., et al.
Publicado: (1997)

Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea
por: Kårhus, Martin Lund, et al.
Publicado: (2022)

Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once‐a‐week versus once‐every‐3‐weeks cisplatin
por: Menon, Nandini S., et al.
Publicado: (2022)

Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
por: Johansen, Pierre, et al.
Publicado: (2019)

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
por: Qiao, Qing, et al.
Publicado: (2016)

Effect of once weekly oral levothyroxine therapy
por: del Toro-Diez, Andrea, et al.
Publicado: (2021)

An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study
por: Galle, Jan-Christoph, et al.
Publicado: (2012)

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma
por: Arrillaga-Romany, Isabel, et al.
Publicado: (2017)

Exenatide once weekly: clinical outcomes and patient satisfaction
por: Jose, Biju, et al.
Publicado: (2010)

Treatment responses with once-weekly teriparatide therapy for osteoporosis
por: Shiraki, M., et al.
Publicado: (2016)

Retiring, Rethinking, and Reconstructing the Norm of Once-Weekly Psychotherapy
por: Schleider, Jessica L., et al.
Publicado: (2020)

Once-Weekly Exenatide in Youth With Type 2 Diabetes
por: Tamborlane, William V., et al.
Publicado: (2022)

The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
por: Vidal, Josep, et al.
Publicado: (2020)

Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study
por: Boye, Kristina, et al.
Publicado: (2020)

Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate
por: Morrison, Laura, et al.
Publicado: (2023)

Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada
por: Sugimoto, T., et al.
Publicado: (2014)

Incremental and Once- to Twice-Weekly Hemodialysis: From Experience to Evidence
por: Obi, Yoshitsugu, et al.
Publicado: (2017)

1420. Successful Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin
por: Van Hise, Nicholas W, et al.
Publicado: (2019)

Efficacy and Safety of Once-Weekly Thyroxine for Thyroxine-Resistant Hypothyroidism
por: Jayakumari, Chellama, et al.
Publicado: (2019)

Preclinical Characterization of Once Weekly Basal Insulin Fc (BIF)
por: Moyers, Julie S, et al.
Publicado: (2021)

Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes
por: Di Dalmazi, Giulia, et al.
Publicado: (2022)

Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus
por: Onishi, Yukiko, et al.
Publicado: (2012)

Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
por: El Khoury, Antoine C, et al.
Publicado: (2021)

Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study*
por: COOPER, A, et al.
Publicado: (2006)

Treatment with once‐weekly alendronate oral jelly compared with once‐weekly alendronate oral tablet for Japanese patients with primary osteoporosis: An open‐label, prospective, observational study
por: Okimoto, Nobukazu, et al.
Publicado: (2018)

C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis
por: Roger, Simon D., et al.
Publicado: (2011)

Once-weekly albiglutide in the management of type 2 diabetes: patient considerations
por: Woodward, Heather N, et al.
Publicado: (2014)

Nonsurgical Corrective Union of Osteoporotic Vertebral Fracture with Once-Weekly Teriparatide
por: Miyakoshi, Naohisa, et al.
Publicado: (2015)

Emerging utility of once-weekly exenatide in patients with type 2 diabetes
por: Goud, Aditya, et al.
Publicado: (2015)

Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent
por: Ayoub, Bassam M., et al.
Publicado: (2018)

Impact of patient background factors on the treatment efficacy of once-weekly teriparatide
por: Omura, Fumitoshi
Publicado: (2019)

How different is the once-weekly teriparatide from the daily one or the same?
por: Takeuchi, Yasuhiro
Publicado: (2019)

Exenatide Once Weekly for Management of Type 2 Diabetes: A Review
por: Inaishi, Jun, et al.
Publicado: (2022)

Fluorescence Biomodulation for Canine Interdigital Furunculosis: Updates for Once-Weekly Schedule
por: Marchegiani, Andrea, et al.
Publicado: (2022)

Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan
por: Juul Kildemoes, Rasmus, et al.
Publicado: (2020)

Cost-Minimization Analysis of Once-Weekly Versus Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia
por: Cremieux, Pierre Y., et al.
Publicado: (2004)

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2017)

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cd8h0ecfjfvpv52d27745315p5